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Background: Specific pathways and components for respiration in Chlamydia are poorly understood.
Results: The C. trachomatis hypothetical protein CT263 crystal structure displays strong structural similarity with 5-methyl-
thioadenosine nucleosidase enzymes.
Conclusion: Bioinformatic analyses and enzymatic characterization of CT263 suggest menaquinone biosynthesis proceeds
through the futalosine pathway in Chlamydiaceae.
Significance: Unique structural aspects of the CT263 active site can be leveraged to modify existing transition state inhibitors.
The obligate intracellular human pathogen Chlamydia tra-
chomatis is the etiological agent of blinding trachoma and sex-
ually transmitted disease. Genomic sequencing of Chlamydia
indicated this medically important bacterium was not exclu-
sively dependent on the host cell for energy. In order for the
electron transport chain to function, electron shuttling between
membrane-embedded complexes requires lipid-soluble quino-
nes (e.g. menaquionone or ubiquinone). The sources or biosyn-
thetic pathways required to obtain these electron carriers within
C. trachomatis are poorly understood. The 1.58Å crystal struc-
ture of C. trachomatis hypothetical protein CT263 presented
here supports a role in quinone biosynthesis. Although CT263
lacks sequence-based functional annotation, the crystal struc-
ture of CT263 displays striking structural similarity to 5-meth-
ylthioadenosine nucleosidase (MTAN) enzymes. Although
CT263 lacks the active site-associated dimer interface found in
prototypical MTANs, co-crystal structures with product (ade-
nine) or substrate (5-methylthioadenosine) indicate that the
canonical active site residues are conserved. Enzymatic charac-
terization of CT263 indicates that the futalosine pathway inter-
mediate 6-amino-6-deoxyfutalosine (kcat/Km  1.8  103 M1
s1), but not the prototypical MTAN substrates (e.g. S-adenosyl-
homocysteine and 5-methylthioadenosine), is hydrolyzed.
Bioinformatic analyses of the chlamydial proteome also support
the futalosine pathway toward the synthesis of menaquinone in
Chlamydiaceae. This report provides the first experimental sup-
port for quinone synthesis in Chlamydia. Menaquinone synthe-
sis provides another target for agents to combat C. trachomatis
infection.
Quinones are lipid-soluble electron carriers essential to cel-
lular respiration in bacteria (1). Although certain bacteria (e.g.
Escherichia coli) utilize different quinones depending on oxy-
gen availability, many Gram-negative and most Gram-positive
bacteria rely on menaquionone (MK)2 as the sole electron car-
rier (2). In higher order eukaryota, MK (also known as vitamin
K2) is a cofactor required for post-translational glutamate mod-
ification essential to a variety of regulatory pathways, including
blood coagulation and bone metabolism (3). As humans are
incapable of synthesizing MK, bacterial enzymes involved in
this pathway are potential targets for the development of novel
antimicrobial therapeutics.
Two distinct biosynthetic routes of MK have been described
in bacteria (Fig. 1), the well studied traditional route (4, 5) and
the recently discovered futalosine route (6). Both routes begin
with chorismate and involve common enzymes at several of the
later steps. Importantly, no organism has been found to possess
a complete set of enzymes required for both the traditional and
futalosine MK biosynthetic routes (6). Thus, the presence of
genes unique to either pathway indicates that complete routes
are encoded. Human commensal bacteria, primarily facultative
anaerobes (e.g. Lactobacillus), typically do not synthesize MK
* This work was supported, in whole or in part, by National Institutes of Health
Grants AI079083 and GM041916.
The atomic coordinates and structure factors (codes 4QAQ, 4QFB, 4QAR, 4QAS,
and 4QAT) have been deposited in the Protein Data Bank (http://wwpdb.org/).
1 To whom correspondence should be addressed: 1200 Sunnyside Ave., Uni-
versity of Kansas, Lawrence, KS 66045. Tel.: 785-864-5392; Fax: 785-864-
5294; Email: pshefty@ku.edu.
2 The abbreviations used are: MK, menaquionone; MTAN, 5-methylthioad-
enosine nucleosidase; MTA, 5-methylthioadenosine; r.m.s.d., root mean
square deviation; SeMet, selenomethionine; AdoHcy, S-adenosylhomocys-
teine; AFL, 6-amino-6-deoxyfutalosine; BisTris, 2-[bis(2-hydroxyethyl)-
amino]-2-(hydroxymethyl)propane-1,3-diol; PDB, Protein Data Bank; ADE,
adenine; UQ, ubiquinone; AdoMet, S-adenosylmethionine; DHFL, dehy-
poxanthinyl futalosine; LCCA, last common chlamydial ancestor; BS3,
bis(sulfosuccinimidyl)suberate.
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 289, NO. 46, pp. 32214 –32229, November 14, 2014
© 2014 by The American Society for Biochemistry and Molecular Biology, Inc. Published in the U.S.A.














(7), and those that do (e.g. E. coli) utilize the traditional route.
The absence of futalosine genes in these organisms strengthens
the development of antimicrobial compounds targeting patho-
genic bacteria that synthesize MK (8).
Chlamydia are obligate intracellular bacteria and include
pathogenic species for which the requisite electron transport
quinone is undetermined. The metabolically active form of
Chlamydia replicates within a microaerophilic environment
inside a modified intracellular vacuole (9). Early speculation
suggested that Chlamydia acquire ubiquinone (UQ) from the
host (10). However, genome sequencing indicated otherwise,
revealing the presence of four UQ biosynthesis homologs that
could play a role in quinone synthesis. As these predicted
enzymes could potentially catalyze reactions found in both UQ
and MK biosynthetic pathways, the predicted quinone biosyn-
thetic pathway of Chlamydia has remained undefined. Previous
reports suggested that Chlamydia possess futalosine enzyme
homologs (8, 11), but these genes were not specifically described.
Here, we present structural, enzymatic, and bioinformatic evi-
dence in support of Chlamydiaceae utilizing the futalosine route
toward the synthesis of MK.
EXPERIMENTAL PROCEDURES
Cloning, Overexpression, and Purification of Recombinant
CT263 from Chlamydia trachomatis—A gene fragment encod-
ing the entire open reading frame (residues 1–196) of ctl0515
was amplified from C. trachomatis (serovar L2 434/Bu)
genomic DNA via PCR and subcloned into BamHI/NotI-di-
gested pT7HmT (12). In keeping with consistent chlamydial
nomenclature, all references to this gene product will utilize the
C. trachomatis D/UW-3 homolog CT263. CTL0515 and CT263
are 99% identical, with a single substitution (A76G) at the
amino acid level. Upon DNA sequence confirmation, the vector
was transformed into BL21(DE3) E. coli competent cells. This
strain was grown to an A600 of 0.8 at 37 °C within Terrific Broth
supplemented with kanamycin (50 g/ml), and protein expres-
sion was induced overnight at 16 °C by the addition of isopropyl
1-thio--D-galactopyranoside to a 1 mM final concentration.
Bacterial cells were harvested by centrifugation, resuspended in
lysis buffer (20 mM Tris-HCl (pH 8.0), 500 mM NaCl, and 10 mM
imidazole), and then lysed by sonication. The soluble His6-la-
beled protein was collected in the supernatant following cen-
trifugation of the cell homogenate and purified on a Ni2-nitri-
lotriacetic acid-Sepharose column according to published
protocols (12). Recombinant tobacco etch virus protease was
used to digest the fusion affinity tag from the target protein.
Both the affinity tag and tobacco etch virus protease were
removed by reverse Ni2-nitrilotriacetic acid-Sepharose chro-
matography. After desalting into 20 mM Tris-HCl (pH 8.0), final
purification was achieved by ResourceQ anion-exchange chro-
matography followed by size exclusion chromatography (GE
Healthcare). The purified protein was concentrated to 10
mg/ml in 20 mM Tris-HCl (pH 8.0), 200 mM NaCl buffer by
ultrafiltration and stored at 4 °C for further use.
Selenomethionine (SeMet)-substituted CT263 was grown
according to standard protocols (13), purified as described
above (all buffers contained 5 mM -mercaptoethanol), and
concentrated to 10 mg/ml in 20 mM Tris-HCl (pH 8.0), 200 mM
NaCl buffer for crystallization.
Crystallization—Recombinant C. trachomatis CT263 was
crystallized by vapor diffusion in Compact Jr. (Emerald Biosys-
tems) sitting drop plates at 20 °C. Specifically, 0.5 l of protein
solution (10 mg/ml in 20 mM Tris-HCl (pH 8.0), 200 mM NaCl)
was mixed with 0.5 l of reservoir solution containing 200 mM
ammonium sulfate, 100 mM sodium acetate trihydrate (pH 4.6),
and 30% (w/v) PEG 2K MME from the Crystal HT screen con-
dition F1 (Hampton) and equilibrated against 75 l of the latter.
Single rectangular prism-shaped crystals appeared after 1 day
and continued to grow for 4 days. Crystals were flash-cooled
in a cryoprotectant solution consisting of mother liquor with
20% (v/v) glycerol. Gold-derivatized CT263 crystals were gen-
erated by incubating native crystals for 24 – 48 h in mother liq-
uor supplemented with 10 mM K2AuCl4. Crystals that had
changed to a yellow color (indicating the likely presence of
ordered gold atoms) were harvested as described above.
SeMet-CT263 crystals were obtained in essentially the same
manner as wild type; however, small block-shaped crystals
required reduced ammonium sulfate concentrations as well as
increased pH and PEG 2K MME. Briefly, protein solution (0.5
l) was mixed with 0.5 l of reservoir solution (50 mM ammo-
nium sulfate, 100 mM BisTris (pH 6.4), and 32% (w/v) PEG 2K
MME) and equilibrated against 100 l of the latter. Small block-
shaped crystals were harvested as described above.
Ligand-bound CT263 crystals were obtained in a similar
manner as wild type. Briefly, CT263 (wild-type or D161N, 10
mg/ml) was incubated with 10 mM MTA on ice for 30 min prior
to crystallization. The ligand/protein solution (0.5 l) was then
mixed with 0.5 l of reservoir solution (200 mM ammonium
sulfate, 100 mM sodium acetate trihydrate (pH 4.6) and 30%
(w/v) PEG 2K MME) and equilibrated against 100 l of the
latter. Large block-shaped crystals were harvested in a similar
manner as described above.
Diffraction Data Collection, Structure Determination, Refine-
ment, and Analysis—X-ray diffraction data were collected on
all CT263 crystals at 1.000 Å at 100 K with the exception of
CT263-Au and SeMet-CT263 crystals, which were collected at
1.03969 Å and 0.97911 Å, respectively, using a Dectris Pilatus 6
M pixel array detector at IMCA-CAT beamline 17ID at the APS
(Table 2). Following data collection, individual reflections from
each dataset were integrated with XDS (14). Laue class analysis
and data scaling were performed with Aimless (15), which sug-
gested the Laue class was mmm. Systematic absences were ana-
lyzed and suggested that the likely space group was P22121 for
all datasets with the exception of SeMet-CT263 (P21221). The
axes were permuted to P21212 using Reindex Reflections in
CCP4 (16) for all datasets, except SeMet-CT263, to adopt
standard space group nomenclature.
Experimental phase information was obtained for the CT263
structure by Au-SAD using AutoSol within the Phenix suite
(17, 18), which identified two unique gold atoms in the asym-
metric unit. Phenix.Autobuild correctly traced 269/392 C
atoms (Map-model CC  0.70, Rwork/Rfree  38.57/43.00)
within two CT263 polypeptides. Anomalous phases were com-
bined with the complete 1.58 Å diffraction dataset using CAD
(16). Subsequently, Phenix.Autobuild (17, 18) was then used to
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trace 309/392 of the expected amino acids from the combined
experimental maps with Rwork/Rfree  26.74/29.77.
The structure of SeMet-CT263 was independently deter-
mined by Se-SAD using AutoSol within the Phenix suite (17,
18), which identified eight unique selenium atoms in the asym-
metric unit. Phenix.Autobuild correctly traced 353/392 C
atoms (Map-model CC  0.85, Rwork/Rfree  21.00/24.98)
within two CT263 polypeptides. Chains A and B of Protein Data
Bank (PDB) entry 4QAQ (wild-type C. trachomatis CT263)
were used as a search model for WT/ADE, apo-CT263D161N,
and CT263D161N-MTA structures.
Structural refinement was carried out using Phenix (17, 18)
for all structures. One round of individual coordinates and iso-
tropic atomic displacement factor refinement was conducted,
and the refined model was used to calculate both 2Fo  Fc and
Fo  Fc difference maps. These maps were used to iteratively
improve the model by manual building with Coot (19, 20) fol-
lowed by subsequent refinement cycles. TLS refinement (21)
was incorporated in the final stages to model anisotropic
atomic displacement parameters. Ordered solvent molecules
were added according to the default criteria of Phenix and
inspected manually using Coot prior to model completion.
Interpretable electron density was absent for the following res-
idues in each structure: apo-WT, chain A, 196 and chain B,
96 –101 and 195–196; apo-D161N, chain B, 97–101, 129 –130,
and 195–196; SeMet-CT263, chain A, 195–196 and chain B,
97–101, 124 –126 and 195–196; WT/ADE, chain A, 196, chain
B, 96 –102 and 195–196; D161N/MTA, chain A, 196 and chain
B, 97–100 and 195–196. Disordered side chains were truncated
to the point where electron density could be observed. Addi-
tional information and refinement statistics are presented in
Table 2.
Enzymatic Assay of CT263—Enzymatic assays were per-
formed in 50 mM HEPES (pH 7.4), 200 mM KCl, 5% (v/v) glyc-
erol and initiated by the addition of recombinant CT263.
CT263 was added to a 200-l reaction volume at a final con-
centration of 250 nM. Enzymatic activity was tested against 50
M of the following substrates: 6-amino-6-deoxyfutalosine
(AFL), S-adenosylhomocysteine (AdoHcy), 5-methylthioad-
enosine (MTA), and adenosine triphosphate (ATP). Samples
were incubated overnight at room temperature and assayed via
HPLC. Product peaks were collected, dried on a speed vacuum,
and analyzed by mass spectroscopy.
Characterization of Steady-state Kinetic Parameters—Activ-
ity with AFL was continuously monitored by UV-visible spec-
trophotometry at 263 nm. Reactions were performed in 1-ml
volumes under similar reaction conditions as above with vary-
ing concentrations of AFL. Reactions were initiated by the addi-
tion of CT263 to final concentrations of 100 –200 nM. A lucif-
erase-coupled assay converted product adenine to ATP in 100
mM Tris-HCl (pH 7.7) (22). Briefly, luminescence was con-
verted to picomoles of adenine (correcting for background and
fitted to a standard curve). Initial rate kinetics (substrate kcat
and Km) were calculated by fitting to the Michaelis-Menten
equation.
Multiple Sequence Alignments and Figure Modeling—Multi-
ple sequence alignments were carried out using ClustalW (23)
and aligned with secondary structural elements using ESPRIPT
(24). Sequences identified by DALI analysis of the CT263 crys-
tal structure and used in alignments, along with their respective
GenBankTM accession numbers, were as follows: C. trachoma-
tis serovar L2 434/Bu (166154474); Chlamydia muridarum
Nigg (15835152); Chlamydia felis Fe-C/56 (89898433); Chla-
mydia caviae GPIC (29840145); Chlamydia pneumoniae
CWL029 (4376692); Chlamydia psittaci 6BC (332287326);
Chlamydia pecorum (566141550); Helicobacter pylori (15644719);
Arabidopsis thaliana (332661576); Francisella philomiragia
(167626574); Sulfurimonas denitrificans (78777589); Staphylo-
coccus aureus (15924589); Streptococcus pneumoniae (15900866);
Vibrio cholerae (9656950); Neisseria meningitidis (15676665);
Salmonella enterica (322713231) and Escherichia coli (1786354).
Three-dimensional structures were superimposed using the
Local-Global Alignment method (25). The following MTAN
structures were obtained from the PDB (26): E. coli (1Z5P), V.
cholerae (3DP9), N. meningitidis (3EEI), S. pneumoniae
(3MMS), H. pylori (4BMZ), S. enterica (4F1W), S. aureus
(4GMH), F. philomiragia (4JOS), and S. denitrificans (4JWT).
Representations of all structures were generated using PyMOL
(27). Calculations of electrostatic potentials at the molecular
surface were carried out using DELPHI (28). The program
CONSURF was used to plot levels of amino acid sequence con-
servation on the molecular surface (29).
RESULTS
Bioinformatic Support of Futalosine Pathway in Chlamydiaceae—
The medically important human pathogen C. trachomatis is
capable of oxidative level phosphorylation, generating ATP
through the electron transport chain (30). However, the source
of electron shuttling quinones has been unclear and is further
compounded by the presence of four genes with homology to
enzymes common to both the UQ and MK biosynthetic path-
ways (10). Recently, an alternative pathway toward the synthe-
sis of MK (Fig. 1), named the futalosine pathway after the first
metabolic intermediate, was described (6). This pathway was
found in bacteria, including Streptomyces, Helicobacter, and
Campylobacter among others, that had previously incomplete
UQ or MK biosynthetic routes.
Iterative BLAST searches of Streptomyces genes involved in
the futalosine pathway against available Chlamydia genome
sequences yielded statistically significant hits for 7 of the 8
enzymes (Table 1), with only the nucleosidase step (fulfilled
by MqnB or MTAN) lacking an identified homolog. As
reported previously (31), despite utilizing S-adenosylmethio-
nine (AdoMet) in a multitude of pathways, Chlamydia para-
doxically appear to lack the MTAN enzyme needed to salvage
products of AdoMet-utilizing reactions.
Analysis of the C. trachomatis transcriptome indicates that
several of the BLAST-identified futalosine genes are co-tran-
scribed (32). CT263, a protein of unknown function, is co-tran-
scribed along with the predicted MqnD homolog (CT262).
However, BLAST analysis of CT263 fails to identify a single
protein of significant similarity outside of Chlamydia. As Chla-
mydia are phylogenetically distinct bacteria, we hypothesized
that despite an absence of sequence similarity, CT263 could
fulfill the nucleosidase enzymatic role (e.g. step 2 in Fig. 1) and
complete the futalosine pathway.
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Despite annotation as a protein of unknown function, the
NCBI Conserved Domain Database indicated CT263 might
contain a provisional nucleosidase domain (PRK05634). To
gain further support that CT263 could fulfill a role as a nucle-
osidase and complete the putative futalosine pathway within
Chlamydia, ab initio modeling of CT263 was performed by the
protein structure prediction platform I-TASSER (33–35). The
highest ranked computational model of CT263 exhibited a
C-score of 0.31, which indicates high confidence in model accu-
racy (C-score  1.5 (36)). The top 10 structural analogs in the
PDB of this model are all MTAN enzymes with r.m.s.d. values
below 2.50 Å. As computational predictions for CT263 support
a potential role as an MTAN enzyme, enzymatic studies using
recombinant protein were initiated to further investigate these
predictions.
Identification of CT263 Substrates and Hydrolyzed Products—
MTAN enzymes have been demonstrated to hydrolyze a variety
of substrates, including 5-methylthioadenosine (MTA), Ado-
Hcy, and 6-amino-6-deoxyfutalosine (AFL) (37–39). Typically,
these enzymes catalyze N-glycosidic bond hydrolysis between
N9 of adenine and C1 of the thioribose. Catalysis occurs upon
protonation at N7 of the substrate, and the Sn1-like transition
state is captured by a catalytic water (SN) with loss of the N-ri-
bosidic bond (N9 –C1) and release of adenine (40 – 43). Effi-
FIGURE 1. Multiple routes toward synthesis of menaquinone in bacteria. The traditional route of menaquinone biosynthesis has been extensively charac-
terized in E. coli and involves seven Men family enzymes (upper). The futalosine route diverges in the first two steps as indicated by blue and red coloring for
routes described in Streptomyces coelicolor/Thermus thermophilus and C. jejuni/H. pylori, respectively. Menaquinone biosynthesis in C. trachomatis (CT) is
predicted to function with the genes for each step indicated (lower; numbered boxes). The yellow-boxed reaction represents the reaction catalyzed by CT263
studied herein. The gray-boxed genes represent ubi/men homologs with predicted prenylation (CT219), methylation (CT428), and decarboxylation activity
(CT085 and CT220) that could function in the final steps of menaquinone synthesis.
TABLE 1
Bioinformatic analysis of futalosine biosynthesis genes in Chlamydia
Futalosine gene Function Chlamydia genes BLAST E-value Sequence identity Query cover
% %
SCO4506a MqnA CT427b CTL0686c 7.00E-12 21 95
SCO4327 MqnB NAd NA
SCO4550 MqnC CT767 CTL0136 1.00E-84 40 85
CT426 CTL0685 2.00E-55 33 87
SCO4326 MqnD CT262 CTL0514 4.00E-43 33 91
SCO4556 ???e CT428 CTL0687 4.00E-36 36 92
SCO4491 ??? CT219 CTL0471 2.00E-36 36 78
SCO4490 ??? CT085 CTL0340 2.00E-72 35 90
SCO4492 ??? CT220 CTL0472 3.00E-23 28 94
Cj1285cf MqnA2 CT427 CTL0686 1.00E-06 25 64
Cj0117 MTAN NA NA
a SCO means S. coelicolor A3 (2).
b CT means C. trachomatis D/UW-3.
c CTL means C. trachomatis L2 434/Bu.
d NA means not applicable.
e ??? means genes predicted to be involved in Futalosine pathway by sequence homology (6).
f Cj means C. jejuni.
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cient processing of these substrates is critical for biochemical
pathways involving the products of AdoMet utilization (44, 45).
Accumulation of MTA is reported to cause feedback inhibition
of polyamine biosynthesis (46, 47) and AdoMet-dependent
methylation events, whereas AdoHcy hydrolysis provides pre-
cursors for biosynthesis of quorum-sensing compounds. Thus,
proper MTAN function is essential to bacteria that require
these pathways.
Purified recombinant CT263 was incubated with a variety of
potential MTAN substrates, including AFL, AdoHcy, MTA,
and ATP. HPLC analysis of the reaction mixtures post-CT263
addition revealed that only AFL resulted in substrate conver-
sion (Fig. 2A). Reaction mixtures containing AdoHcy or MTA
did not result in substrate conversion (data not shown), indi-
cating that CT263 does not function as a canonical MTAN. The
product peaks generated by HPLC were confirmed via Fourier
transform mass spectrometry (Fig. 2, B–D) to be that of adenine
and dehypoxanthinyl futalosine (DHFL). The observed mass of
DHFL indicates that the water-bound intermediate was not
observed and is likely unstable under these conditions. Cataly-
sis of AFL to adenine and DHFL indicates that CT263 likely
functions within the futalosine pathway (Fig. 1). However, the
absence of MTA/AdoHcy hydrolytic activity suggests that in
contrast to the bioinformatic predictions, CT263 does not
function as a prototypical MTAN.
Kinetic Characterization of Wild-type C. trachomatis CT263—
The ability of CT263 to hydrolyze AFL was further investigated
under steady-state conditions (Fig. 3). The results of this assay
reveal an apparent Km of 8.3  0.9 M. The kcat derived from
fitting the curve to the equation for substrate inhibition is
0.91  0.3 min1. Despite the relatively low catalytic efficiency
(kcat/Km value of 1.8 	 103 M1 s1), CT263 is competent for
AFL hydrolysis. In the absence of strong selective pressure (e.g.
synthesis of secondary metabolites), enzyme catalytic rates typ-
ically do not evolve toward maximal levels. The catalytic effi-
ciency of an average enzyme is 1 	 105 M1 s1; however,
enzymes that function within secondary metabolite pathways
are, on average, 30 times slower (48). Thus, the enzymatic rate
FIGURE 2. Identification of CT263 substrates and hydrolyzed products. A, HPLC reaction traces showing unreacted AFL (black) and the reaction products
after addition of CT263 (blue). Reactions were initiated by the addition of CT263 (250 nM) and allowed to react overnight. B–D, mass spectrometry data for the
starred peaks in A. The isolated peaks indicated by the corresponding asterisk were analyzed on a Varian 12T Fourier transform mass spectrometer in both
positive and negative modes. B, spectra were obtained in negative mode. Boxed peak corresponds to the calculated mass of adenine. C, spectra were obtained
in negative mode. Boxed peaks correspond to the calculated mass of DHFL minus water and AFL. D, spectra were obtained in positive mode. Boxed peaks
correspond to the calculated mass of AFL.
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of CT263 is actually in line with the average rate of previously
characterized secondary metabolite enzymes.
The catalytic efficiency of MqnB/MTAN enzymes with
broader specificity, including both MTA and AFL, is greater.
The MTANs from Campylobacter jejuni and Helicobacter
pylori were reported to give kcat/Km values of 5.3 	 105 and
5.4 	 106 M1 s1, respectively (47, 50). Although the kcat value
of CT263 is similar, its Km value is complicated by substrate
inhibition, where larger concentrations of AFL inhibit catalysis,
with a dissociation constant of 154 M (Fig. 3). It is important to
note that enzymes within bacterial vitamin/cofactor pathways
typically exhibit modest catalytic capacity. For example, the
FIGURE 3. Enzymatic characterization of CT263. Initial rate (lumens/s) of catalytic activity with increasing concentrations of CT263 (left panel) and plotted as
a function of increasing substrate (F, AFL) concentration (right panel). Rate kinetics (substrate kcat and Km and product Kis) were calculated by fitting to the
Michaelis-Menten equation. Assay conditions (luciferase-based) are detailed under “Experimental Procedures.”
TABLE 2
X-ray diffraction data and structure refinement
CT263 native CT263 fold CT263 SeMet CT263 adenine CT263, D161N native CT263 D161N MTA
PDBcode 4QAQ 4QFB 4QAR 4QAS 4QAT
Data collection
Unit-cell parameters (Å) a  65.96, b  104.5,
c  58.31
a  65.24, b  103.8,
c  57.92
a  60.85, b  74.23,
c  78.06
a  65.64, b  104.5,
c  58.21
a  65.44, b  104.2,
c  58.15
a  65.88, b  104.3,
c  58.22
Space group P21212 P21212 P21221 P21212 P21212 P21212
Resolution (Å)a 55.77-1.58 (1.62-1.58) 43.31-2.60 (2.71-2.60) 47.99-1.99 (2.03-1.9) 65.64-1.45 (1.45-1.47) 104.15-1.25 (1.27-1.25) 104.26-1.75 (1.78-1.75)
Wavelength (Å) 1.0000 1.03969 0.97911 1.0000 1.0000 1.0000
Temperature (K) 100 100 100 100 100 100
Observed reflections 365,303 (17,639) 78,252 (9,308) 153,450 (10,199) 441,820 (19,724) 714,770 (33,502) 271,538 (15,179)
Unique reflections 56,011 (2,751) 12,572 (1,504) 24,951 (1,672) 71,123 (3,459) 110,407 (5,413) 41,202 (2,223)

I/(I)a 14.8 (2.2) 17.2 (4.8) 14.5 (4.1) 15.7 (2.5) 14.5 (1.9) 13.5 (2.0)
Completeness (%)a 100.0 (100.0) 99.5 (99.4) 99.4 (95.3) 99.3 (99.5) 100.0 (99.9) 99.9 (99.9)
Multiplicitya 6.5 (6.4) 6.2 (6.2) 6.2 (6.1) 6.2 (5.7) 6.5 (6.2) 6.6 (6.8)
Rmerge (%)a,b 6.0 (85.7) 6.3 (33.6) 7.5 (38.1) 7.6 (92.9) 5.3 (92.1) 8.0 (94.3)
Rmeas (%)a,c 7.1 (102.0) 7.4 (40.2) 8.9 (45.8) 8.3 (102.8) 5.7 (100.5) 8.7 (102.0)
Rpim (%)a,c 3.8 (54.7) 3.9 (16.4) 4.8 (24.8) 3.4 (43.2) 2.2 (39.8) 3.4 (38.6)
CC1/2 d 99.9 (78.6) 99.7 (91.4) 99.7 (92.9) 98.6 (79.4) 99.9 (74.1) 99.9 (78.5)
Phasing
Anom, completeness (%)a 96.7 (95.9) 92.8 (89.7)
Anom. multiplicitya 3.2 (3.1) 2.9 (2.8)
FOM 33.6 27.9
Refinement
Resolution (Å) 40.95-1.58 39.04-1.99 33.45-1.45 33.37-1.25 43.62-1.75
Reflections (working/test) 55,591 (2,840) 23,618 (1,880) 70,635 (3,573) 110,323 (5,516) 41,136 (2,069)
Rfactor/Rfree (%)e 16.56/19.87 16.65/2.16 18.69/21.68 17.76/19.54 16.56/19.57
No. of atoms (protein/ligand/solvent) 2,980/0/234 3,050/0/136 3,007/10/310 3,021/0/419 3,054/20/241
Model quality
r.m.s.d.
Bond lengths (Å) 0.009 0.012 0.010 0.009 0.010
Bond angles (o) 1.026 1.109 1.059 1.071 1.105
All-atom Clashscore 0.17 1.37 0.83 3.25 1.65
Average B-factor (Å2)
All Atoms 30.4 27.54 21.9 25.3 34.3
Protein 30.0 27.48 21.1 24.1 33.9
Ligand NA NA 31.4 NA 37.5
Solvent 36.4 28.79 29.6 34.6 38.6
Coordinate error, maximum likelihood (Å) 0.15 0.19 0.16 0.14 0.19
Ramachandran Plot
Most favored (%) 97.9 96.3 97.9 97.3 97.9
Additionally allowed (%) 2.1 3.2 2.1 2.6 2.1
Outliers (%) 0.0 0.5 0.0 0.3 0.0
a Values in parentheses are for the highest resolution shell.
b Rmerge  hkliIii(hkl)  
I(hkl)/hkliIi(hkl), where Ii(hkl) is the intensity measured for the ith reflection and 
I(hkl) is the average intensity of all reflections with indices
hkl.
c Rmeas  redundancy-independent (multiplicity-weighted) Rmerge (15, 66). Rpim  precision-indicating (multiplicity-weighted) Rmerge (67, 68).
d CC1/2 is the correlation coefficient of the mean intensities between two random half-sets of data (65, 69).
e Rfactor  hklFobs (hkl)  Fcalc (hkl)/hklFobs (hkl); Rfree is calculated in an identical manner using 5% of randomly selected reflections that were not included in the re-
finement (SeMet-CT263  8%).
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synthesis of an electron carrier within Actinomycetes has a
reported kcat/Km of 2.0 M1 s1 (49), roughly 900 times less
efficient than CT263. To further understand the enzymatic
properties of CT263, recombinant protein was entered into
crystallization trials so that the catalytic site could be structur-
ally investigated.
1.58 Å Crystal Structure of CT263 from C. trachomatis—
Orthorhombic crystals (P21212) of CT263 were grown, and the
structure was determined by Au-SAD (all molecular replace-
ment phasing attempts with homology models were unsuccess-
ful) and refined against native x-ray diffraction data to a reso-
lution of 1.58 Å (Table 2). CT263 is composed of a single
globular domain (Fig. 4A) with dimensions 30 	 30 	 45 Å.
The mixed / fold of CT263 consists of a central core of 10
twisted -sheets flanked by two sets of paired -helices with the
following topology: 1-1-2-3-4-2-5-6-7-8-9-3-
10-4-5. Two polypeptides were found within the asymmet-
ric unit. Numbering of all residues in this work reflects their
position in the C. trachomatis CT263 sequence.
In contrast to all other CT263 structures presented herein,
selenomethionine-labeled CT263 crystallized in a different
orthorhombic space group (P21221). Structural superposition
of both experimentally determined CT263 protomers indicates
that they are highly similar to each other, with an r.m.s.d. of 0.29
Å across all C atoms. Additionally, two polypeptides are also
found within the asymmetric unit (Fig. 4B).
Consistent with a potential enzymatic function, the CT263
structure contains a large, surface-exposed cleft (black circle in
Fig. 4C) predominantly formed by 2, 4, and the loop con-
necting 8-9. Additionally, the putative active site cleft of
CT263 is characterized by a high degree of electronegative
charge density (Fig. 4C). This striking feature likely reflects an
important contribution to substrate binding. Structural super-
position of the computational I-TASSER model and x-ray crys-
tal structure of CT263 (Fig. 4D) validates the high confidence of
the ab initio modeling process with an impressive r.m.s.d. of 2.0
Å across all C atoms. Although the core fold of each structure
is highly similar, modeled loop regions in the I-TASSER struc-
FIGURE 4. Crystal structure (1.58 Å) of CT263 from C. trachomatis. A, crystal structure of CT263 is shown in cartoon ribbon format using common rainbow
colors (slowly changing from blue N terminus to red C terminus). Secondary structure lacking interpretable electron density is shown as dashed line. B, structural
superposition of CT263 dimers from P21212 (apo- and ligand-bound) and P21221 (SeMet) crystals shown in cartoon ribbon format. Wild-type CT263 dimer (gray)
is generated by applying the symmetry operator (x2,y,z), although the SeMet-CT263 dimer (red) is found within the asymmetric unit. Phe-187 side chains
(cyan, balls-and-sticks) participating in - bonding and highlight the 2-fold symmetry within this interface. C, surface representation of electrostatic potential,
generated by DelPhi (28), of CT263 (same orientation as A). Color scheme represents regions of negative (red) and positive (blue) charge density contoured at
5 e/kT. Putative active site cleft is highlighted by a black circle. D, structural superposition of I-TASSER (33–35) computational model depicted in cartoon
ribbon format (blue, -helices; yellow, -sheets; random coil, green) and 1.58 Å crystal structure of CT263 (cartoon ribbon format, colored red). Two structures
align with an r.m.s.d. of 2.0 Å across all C atoms.
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ture are quite different. These model errors likely account for
the unsuccessful use of the I-TASSER model in molecular
replacement and could potentially reflect the altered enzymatic
profile of CT263.
Oligomeric State of CT263 in Solution—As two polypeptides
were found within both CT263 and SeMet-CT263 asymmetric
units, the protein interfaces and assemblies (PISA) server (28)
was used to assess potential modes of oligomerization. The
most thermodynamically favorable assembly was predicted to
be a dimer; however, PISA analysis indicated multiple potential
interfaces could be adopted within either crystal system.
Intriguingly, only one interface is found within both structures
(Fig. 4B), suggesting it could be physiologically relevant. This
interface buries 536 Å2 (6% of the available surface area) with
a predicted G of 4.1 kcal/mol and exhibits 2-fold crystallo-
graphic symmetry (operator: x  2, y,z). Several side chains
from each protomer are within hydrogen bonding distance
(2.5–3.4 Å) and, along with numerous hydrophobic contacts,
stabilize the interface. These interactions include Arg-16 –Ser-
19, Gln-180 –Leu-20, Tyr-190 –Glu-184, and Tyr-22–Glu-184.
Additionally, the side chains of Phe-187 from each protomer
participate in - bonding (Fig. 4B). To provide support for
this dimer, the oligomeric state of CT263 was further analyzed
in solution.
Analytical gel filtration chromatography was used to investi-
gate the oligomeric state of CT263 in solution (Fig. 5A), which
indicated that wild-type CT263 eluted as a single tailed peak
with an apparent molecular mass of 33.7 kDa. This value is
much larger than would be expected for monomeric CT263
(22 kDa), yet smaller than for a dimer (44 kDa). Reversible
association in solution is a common phenomenon with protein
oligomeric assemblies. Previous analysis of the effects of revers-
ible dimerization during gel filtration chromatography pro-
vides insight into the CT263 chromatogram (50). A tailed peak
with a retention time in between those of monomer and dimer
suggests fast dimer association and dissociation, supporting the
potential for CT263 to dimerize.
As analytical gel filtration chromatography analysis of
CT263 did not conclusively indicate a dimeric state was
adopted in solution, the chemical cross-linker BS3 (amine-to-
amine, 11.4 Å spacer length) was utilized to probe for the for-
mation of higher order complexes (Fig. 5B). Incubation of
CT263 (50 M) with 100 M BS3 leads to the formation of a
single higher order band of the approximate molecular weight
for a CT263 dimer. Increasing concentrations of BS3 failed to
produce any higher molecular weight bands (data not shown).
Altogether, these observations provide support that the sym-
metric CT263 dimer likely exists in solution.
Structural Similarities Suggest CT263 Is an MTAN—The
PDB was queried with the protein structure homology server
DALI (51) to identify functionally characterized proteins that
are structurally similar to CT263. The top five scoring unique
hits are listed in Table 3. Each of these structures, as well as the
next 50 hits, is an MTAN enzyme. Each of these structures
aligns to CT263 with an r.m.s.d. of 2.50 Å or lower, and the
overall topology of CT263 is consistent with the consensus
FIGURE 5. Analysis of the CT263 quaternary structure in solution. A, purified CT263 was injected onto an analytical gel filtration column (Superdex 75 10/300
GL, GE Healthcare), and the elution profile (bottom table) was compared with a series of known standards (top table; Bio-Rad) to derive an estimation of protein
molecular weight. The standards are shown as black circles (log Mr versus elution volume plot, R
2  0.9997), and CT263 is represented as a white square. B,
purified CT263 (50 M) was incubated with the amine-reactive cross-linking agent BS3 (100 M) at room temperature for 60 min, quenched with 100 mM Tris-HCl
(pH 7.5), and analyzed by SDS-PAGE. Apparent Mr of CT263 monomer and dimer indicated by black arrows. 1st lane contains protein ladder.
TABLE 3
CT263 DALI search statistics
CT263 structural homology, top 5 (unique) DALI scores
Protein name PDB code Z-scorea r.m.s.d. C rangeb % IDc
MTAN, H. pylori 4BMZ 22.3 2.2 189/230 16
MTAN, A. thaliana 2H8G 21.6 2.4 191/246 17
MTAN, F. philomiragia 4JOS 21.5 2.3 188/230 13
MTAN, S. denitrificans 4JWT 21.4 2.4 191/245 14
MTAN, S. aureus 3BL6 20.9 2.4 186/230 16
a Similarity score representing a function that evaluates the overall level of similar-
ity between the two structures. Z-scores higher than 8.0 indicate that the two
structures are most likely homologous (51).
b Data denote the number of residues from the query structure that superimpose
within an explicit distance cutoff of an equivalent position in the aligned
structure.
c Data denote the percent sequence identity across the region of structural
homology.
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MTAN fold (Fig. 6A). These observations are consistent with
the high degree of structural similarity between the CT263
computational model and crystal structures.
There are several notable structural differences between
CT263 and the queried MTANs (four regions highlighted in Fig.
6) that could potentially account for the altered enzymatic pro-
file of CT263. Helix 2 typically involves at least four turns in
prototypical MTANs, yet only completes two turns within
CT263 (region 1 in Fig. 6A). Perhaps the most pronounced
structural difference within CT263 is found within the loop
region connecting 6-7 (region 2 in Fig. 6A). This region is
typically involved in dimerization (Fig. 7), where it contributes
side chains involved in active site interactions within all struc-
turally characterized MTANs (41, 52–58). The absence of this
region reflects the altered CT263 dimer assemblies relative to
the prototypical MTAN dimer interface. Within canonical
MTANs, the loop connecting 7-8 is typically -helical
(region 3 in Fig. 6A; 3 in E. coli MTAN in Fig. 6B); however,
this region is composed of a random coil in CT263. The role of
3 in prototypical MTAN functionality is currently unclear.
Finally, region 4 of CT263 also adopts a random coil conforma-
tion instead of -helical structure. This region is involved in the
canonical MTAN dimer interface. Despite these numerous
peripheral structural differences, the core fold of CT263 clearly
resembles prototypical MTANs.
The high degree of structural conservation between CT263
and prototypical MTANs is remarkable given the absence of
significant sequence level homologs to CT263. Multiple
sequence alignment of CT263 with the most structurally simi-
lar MTANs (Fig. 6B) identified by DALI (highest sequence
identity: A. thaliana MTAN, 17%; Table 3) provides a plausible
explanation for the absence of the canonicalMTAN dimer
interface. CT263 is composed of 196amino acids, and the short-
est MTAN analyzed in this study (S. aureus, PDB code 3BL6)
FIGURE 6. Structure and sequence conservation of CT263 and MTAN members. A, structural superposition of E. coli MTAN (PDB code: 1Z5P, gray) and CT263
(cyan) structures depicted in cartoon ribbon format and translated apart for clarity. Several regions of structural difference are highlighted in red (E. coli MTAN)
and numbered on each structure. Secondary structure lacking interpretable electron density within CT263 is shown as dashed line (residues 96 –101). B, limited
structure-based alignment of CT263 and MTAN members from the DALI search (Table 3) (51) was generated using ClustalW (23) and rendered with ESPRIPT
(24). The numbers above the sequences correspond to C. trachomatis CT263. The secondary structure of CT263 is shown above the alignment, and the
secondary structure of E. coli MTAN (PDB code: 1Z5P) is shown below. Numbered regions correspond to structural differences highlighted in A. Residues are
colored according to conservation (cyan, identical, and purple, similar) as judged by the BLOSUM62 matrix. Red stars below the sequences correspond to
catalytic triad amino acid side chains; blue stars correspond to adenine-bound side chains, and green stars correspond to ribosyl-bound side chains in the
CT263D161N-MTA structure; and the black star corresponds to the active site CT263 side chain that is disordered in the absence of ligand. Accession numbers are
detailed under “Experimental Procedures.”
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was composed of 228 amino acids.Multiple sequence alignment
indicates that the majority of thisdifference is localized to a
single contiguous stretch of CT263(primarily involving regions
2 and 4 in Fig. 6). Additionally, theresidues that are present
within region 3 are in poor sequence-level agreement with the
queried MTAN structures.
Even though the prototypical MTAN dimer interface is
absent within CT263, the amino acids that are highly conserved
cluster within the surface-exposed cleft of CT263 (Fig. 8A), as
determined by the evolutionary conservation server Consurf
(29). Furthermore, the extensively studied catalytic triad of car-
boxylic acid side chains that are critical for enzymatic MTAN
function (41) are conserved in CT263 (red stars in Fig. 6B) and
located within the putative active site cleft. Accordingly, the
structural similarities between CT263 and canonical MTANs
clearly support the observed nucleosidase activity. In addition,
the significant structural differences also provide a plausible
explanation for the absence of MTA/AdoHcy hydrolytic activ-
ity because of the absence of dimer-mediated active site
interface.
Structural Insights into the CT263 Active Site through Sub-
strate and Product Binding—To further investigate the func-
tion of CT263 and the nature of substrate binding, AFL was
incubated with CT263 prior to crystallization. However, upon
inspection of the resulting electron density maps, no unac-
counted for density was visible within the putative active sites
(data not shown). Thus, in light of the apparent inability of
CT263 to efficiently hydrolyze MTA (substrate image in Fig.
8B), we hypothesized that this compound could be utilized to
further investigate the function of CT263 with respect to the
nature of substrate binding. Wild-type CT263 was incubated
with MTA prior to crystallization, and the resulting crystals
diffracted x-rays to 1.45 Å (Table 2). A single region of unac-
counted for electron density was visible up to 5.0  within only
one active site cleft (Fig. 8C) of the asymmetric unit dimer.
However, it appears that the incubated substrate was actually
hydrolyzed by the crystallized enzyme, as the electron density
perfectly accommodated an ADE molecule (complex termed
WT-ADE, Fig. 9A). The same protein sample of wild-type
CT263 was used in all crystallization trials, suggesting the ade-
nine molecule was not an artifact of co-purification, a common
occurrence in MTAN crystal structures (54, 58). Given the
kinetic characterization of CT263, MTA hydrolysis was rather
unexpected; however, it is noteworthy that the time scale of
crystallization was significantly longer than the enzymatic assay
(18 h incubation with 250 nM of CT263). This specific catalytic
functionality is therefore not likely to be biologically relevant.
Numerous protein contacts are within hydrogen bonding
distance of adenine (Fig. 9A and Table 4), including the side
chain of the catalytic triad residue Asp-161, main chain atoms
from Phe-72 and Gly-74 that are found within a highly con-
served region of prototypical MTANs (blue stars in Fig. 6B),
and main chain atoms from Tyr-124. The WT-ADE structure is
almost identical to the apo-CT263 structure, with an r.m.s.d. of
0.50 Å across all residues. However, the loop connecting 8 and
9 has shifted 1.5 Å toward the substrate, and two side chains
(Arg-125 and Gln-168) near the bound adenine have reoriented
(middle panel in Fig. 9B), further constricting the active site
cleft and reducing solvent exposure to the bound product.
In pursuit of a nonhydrolyzed enzyme-substrate complex,
Asp-161 was mutated to Asn (CT263D161N), a substitution that
has previously proven adventitious in obtaining enzyme-sub-
strate complexes (41, 57). CT263D161N was expressed, purified,
and crystallized in essentially the same manner as wild-type
CT263. The structure of apo-CT263D161N was determined to
1.27 Å (Table 2) and shares near-identity with wild-type CT263
giving an r.m.s.d. of 0.28 Å across all residues. MTA was incu-
bated with mutant CT263D161N prior to crystallization, and the
resulting crystals diffracted x-rays to 1.75 Å (Table 2). In con-
trast to wild-type enzyme, the substrate appeared to be intact as
a larger region of contiguous electron density was again appar-
ent within only a single active site of the CT263D161N asymmet-
ric unit dimer (Fig. 8D). Unexpectedly, the mutant-substrate
complex (termed CT263D161N-MTA) remained in a nearly
identical structural conformation as ADE-bound wild-type
CT263, as judged by structural alignment (r.m.s.d. values of
0.35 Å across all residues). The same residues that reoriented in
the WT-ADE structure are in identical positions in the
CT263D161N-MTA structure. Additionally, interactions with
the purine base of MTA are equivalent to those described in the
WT-ADE complex. Importantly, the bonding distances between
mutant Asn-161 and bound ligand (2.6 Å/N7 and 2.9 Å/N6 for
WT-ADE and 3.1 Å/N7 and 3.1 Å/N6 for CT263D161N-MTA)
are much longer in the mutant complex, indicating proton
donation to N7 of the adenine moiety is likely significantly
reduced by this substitution.
FIGURE 7. Dimer-mediated contacts within prototypical MTANs. Physio-
logic dimer of MTA-bound E. coli MTAN (PDB code: 1Z5O) shown in cartoon
ribbon format. Each protomer is individually colored (orange and cyan). MTA
molecule (balls-and-sticks, yellow) modeled in each active site. Catalytic triad
and dimer-mediated aromatic residues are shown as balls-and-sticks and col-
ored purple. Inset, dashed box indicates magnified active site region.
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Protein contacts with the MTA sugar moiety (Fig. 9C, Table
4, and green star in Fig. 6B) involve hydrogen bonding interac-
tions between the ribosyl 2- and 3-hydroxyls and both Glu-
138 oxygen atoms as well as the main chain nitrogen of Met-137
(an invariant MTAN residue). The nucleoside region of MTA
adopts a C4-endo sugar pucker and a syn ribosidic bond, indic-
ative of a high energy conformation. Identification of the cata-
lytic water is slightly confounded by the presence of four waters
at the base of the active site cleft (red spheres in Fig. 9C). The
presence of a “water-wire” channel for the catalytic nucleophile
was previously observed in S. enterica MTAN (SeMTAN (54)).
Within the CT263D161N-MTA structure, only one of these four
waters is within appropriate bonding distance of the catalytic
triad residue Glu-13 (2.6 Å) and C1 (3.6 Å) of MTA (large red
sphere in Fig. 9C), indicating this water is the most likely SN
candidate.
The 5-alkylthio side chain of MTA lacks any noticeable
hydrogen bonding interactions with CT263D161N; however, the
side chain of Trp-48 forms a hydrophobic barrier parallel to this
region of MTA (Fig. 9C; distance of 3.8 Å at each atom).
Intriguingly, side chain density for Trp-48 was disordered in all
previously discussed structures (including SeMet-CT263). This
indicates that the presence of MTA increases protein order
within CT263. Active site stabilization in CT263 gives some
insight into the potentially unique mechanism of CT263-sub-
strate binding, as this aromatic residue is absent from prototyp-
ical MTANs (black star in Fig. 6B). Typically, MTANs encode
an aromatic side chain (Phe/Tyr) on a loop from the second
monomer, which occludes the active site of the first monomer
upon substrate binding (Fig. 7). In SeMTAN, the 5-alkylthio
side chain of the transition state inhibitor MT-DADMe-ImmA
was not within hydrogen bonding distance of this aromatic res-
idue (Tyr-107); instead, extension of the 5-alkylthio side chain
by three carbons placed the ligand within hydrogen bonding
distance of this residue (54). Providing further support for a
unique role in substrate binding, Trp-48 is conserved through-
out all chlamydial orthologs of CT263 (red star in Fig. 10). Alto-
gether, these observations suggest that Trp-48 could poten-
tially account for the lack of dimer-mediated contacts at the
5-alkylthio-binding site within CT263.
Structural Comparison with SeMTAN Reveals That CT263 Is
in the Closed Form—MTANs have been extensively studied
from a structure/function standpoint in a variety of medically
relevant pathogens, including E. coli (41, 56, 58), H. pylori (52,
53, 57, 59), S. aureus (60), and S. enterica (54), among others. All
of these structures have crystallized with a conserved dimer
interface (Fig. 7), involving a region that is absent within CT263
(regions 2 and 4 within Fig. 6). The absence of this interface
within CT263 resulted in the potential presence of novel
dimeric contacts (Fig. 4B). The presence of a single occupied
active site in substrate-bound complexes, as described within
the ligand-bound CT263 structures, is quite common in proto-
FIGURE 8. Structural insights into CT263 active site. A, conservation plot of surface-exposed CT263 amino acid side chains, as generated by CONSURF (29).
Color scheme depicts strongly conserved side chains in red. Putative active site cleft is highlighted by black circle and catalytic triad residues are labeled
(red stars in Fig. 6B). B, Fo  Fc map (green mesh at 4.0  contour) of the fully refined CT263
WT-ADE structure in the absence of modeled ligands (ADE shown for
clarity). Catalytic triad side chains are depicted as balls-and-sticks (purple). Backbone is depicted in cartoon ribbon format (orange). C, MTA. D, Fo  Fc map (green
mesh at 4.0  contour) of the fully refined CT263D161N-MTA structure in the absence of modeled ligands (MTA shown for clarity). Coloring is the same as B.
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typical MTANs (52, 54, 59). The recent structure of ligand-
bound SeMTAN highlights this effect, where one monomer
was in the “closed” form, and the other remained empty and in
the “open” form (54). Structural superposition of both open and
closed SeMTAN monomers and the substrate-bound CT263D161N-
MTA monomer (Fig. 11) indicates that CT263 is in a similar
conformation as ligand-bound SeMTAN (r.m.s.d. of 1.90 and
2.05 Å for closed and open conformations, respectively), partic-
ularly within the active site cleft (boxed region in Fig. 11). As the
CT263WT and CT263D161N-MTA structures adopted highly
similar conformations, these observations suggest that CT263
is constitutively found in a closed-form conformation that is the
substrate binding competent.
Molecular Modeling of 6-Amino-6-deoxyfutalosine Binding—
Despite the fact that MTA was hydrolyzed within wild-type
CT263 crystals, enzymatic analysis of CT263 indicates a pref-
erence for the futalosine pathway intermediate (Fig. 1), AFL.
Efforts to co-crystallize CT263D161N with AFL failed to reveal
novel regions of electron density in either active site cleft. How-
ever, given that the adenosyl moiety is structurally conserved
across MTA, AdoHcy, and AFL, the CT263D161N-MTA com-
plex was used to model the binding location of AFL within the
CT263 active site cleft (Fig. 12). As the structure of CT263
appears to represent a closed form conformation, residues con-
tributing to binding of the aromatic isophthalic acid group of
AFL are likely close to their current position. The only residue
within this region capable of - bonding with the benzene
ring of AFL is Trp-48, the position of which is supported by the
CT263-AFL model and D161N-MTA complex. Additional
binding specificity could originate from Lys-172 and Lys-175
(found on either side of the 4-5 kink), which are appropri-
ately positioned to interact with the carboxylic acid moiety of
AFL. Further studies exploring AFL binding could provide
insights into the development of specific transition-state inhib-
itors and anti-chlamydial compounds.
DISCUSSION
In order for a functional electron transport chain to
assemble within Chlamydiaceae, lipid-soluble electron car-
riers (e.g. quinones) must be present. The potential source of
quinones within Chlamydiaceae has yet to be established,
with early speculation that they were scavenged from the
host (10). However, the presence of a host scavenging trans-
locator or complete quinone biosynthetic pathway was not
FIGURE 9. Ligand-bound crystal structures of CT263. A, 2Fo  Fc map (blue mesh at 1.0  contour) of the refined CT263
WT-ADE structure with one adenine
molecule (balls-and-sticks, yellow) modeled in the active site. Active site side chains within hydrogen bonding distance (2.5–3.5 Å) of adenine are depicted as
balls-and-sticks (purple), and CT263 backbone is depicted in cartoon ribbon format (orange). Further information on these distances can be found in Table 4. B,
surface representation of CT263 structures depicting structural changes that occur upon binding ADE (orange surface) or MTA (green surface). Side chain
residues for Arg-125 and Gln-168 reorient upon ligand binding (solid circle). Ordered electron density for Trp-48 (dashed circle) is only seen within MTA-bound
structure (green). C, 2Fo  Fc map (blue mesh at 1.0  contour) of the refined CT263
D161N-MTA structure with one MTA molecule (balls-and-sticks, yellow)
modeled in the active site. Active site side chains within hydrogen bonding distance (2.5–3.5 Å) of MTA are depicted as balls-and-sticks (cyan), and CT263D161N
backbone is depicted in cartoon ribbon format (green). Further information on these distances can be found in Table 4. Putative catalytic water is shown as a
sphere (red).
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revealed upon genomic sequencing. Here, we provide the
first experimental evidence that Chlamydiaceae can synthe-
size MK through the futalosine route, for potential use dur-
ing oxidative cellular respiration.
Although the crystal structure of CT263 displays a high level
of structural similarity with MTANs (Fig. 6A), the enzymatic
characterization of CT263 indicates that only AFL can be
hydrolyzed at a physiological rate. Traditionally, MTANs
hydrolyze intermediates of AdoMet utilization pathways (37–
39), which include substrates that were not processed by CT263
(e.g. MTA and AdoHcy, Fig. 9, B and C). Chlamydiaceae lack the
apparent homologs necessary to process the products of
MTAN-cleaved MTA and/or AdoHcy (10); however, the pres-
ence of a conserved AdoMet/AdoHcy antiporter (31) poten-
tially alleviates the need for CT263 to deal with these metabo-
lites and could account for the apparent lack of this enzymatic
function.
We have provided structural evidence that CT263 adopts a
novel dimer interface (Fig. 4B) compared with prototypical
MTANs and that a single indel (region 2 within Fig. 6B) is
responsible for the missing region. Typically, upon substrate
binding the MTAN active site is stabilized by both polypeptides
of the dimer, with the residues responsible for interaction with
the 5-alkylthio moiety (dashed box in Fig. 7) coming from the
region absent in CT263. Conversely, as the presented ligand-
bound CT263 structures reveal, the nucleoside-binding pocket
is highly similar to prototypical ligand-bound MTANs (Fig. 11).
Thus, the presence of a unique Trp (residue 48 within CT263,
see black star in Fig. 6B) within the active site pocket might
provide a stabilizing hydrophobic “platform” that could
account for the lack of dimeric contacts typically present within
the active site. The hypothesis that Trp-48 is sufficient to sta-
bilize ligand binding is supported by the CT263D161N-MTA
structure (Fig. 9C). However, the presence of this novel active
site side chain does not explain the fact that CT263 was unable
to efficiently hydrolyze MTA and AdoHcy (Fig. 9, B and C).
These two prototypical MTAN ligands lack the aromatic iso-
phthalic moiety present within 6A6F. Thus, potential -
bonding interactions with Trp-48 could properly position 6A6F
for nucleophilic attack in the wild-type enzyme. Further studies
exploring the contribution of Trp-48 to enzyme catalysis in
CT263 are warranted.
Despite numerous similarities with Chlamydiaceae, includ-
ing an obligate intracellular, biphasic developmental cycle,
environmental Chlamydiales (e.g. Protochlamydia, Parachla-
mydia, Waddlia, and Simkania, among others) feature
enhanced metabolic capabilities (61). Intriguingly, included
among these additional pathways is a complete set of genes for
the synthesis of MK through the traditional route (e.g. menA-G,
Fig. 1). BLAST analysis of genes involved in the first four reac-
tions of the futalosine pathway (including CT263) fails to iden-
tify any statistically significant targets within the environmental
Chlamydiales. This indicates that only the traditional MK bio-
synthetic pathway is present within environmental Chlamydia-
les. As Chlamydiaceae and the environmental Chlamydiales are
the closest evolutionary relatives to each other, the presence
of differing pathways is extremely intriguing yet currently
unexplained.
Chlamydia genomes have undergone a large degree of
reductive evolution, Chlamydiaceae more so than environ-
mental Chlamydiales given the 2–3 times smaller genomes
found within that order (62). The environmental Chlamyd-
iales are significantly more metabolically flexible than Chla-
mydiaceae, encoding additional genes involved in sugar uti-
lization, a complete TCA cycle, and an expanded electron
transport chain, among other pathways (61). As no organism
has been found to simultaneously possess both MK biosyn-
thetic pathways, it seems unlikely that the last common chla-
mydial ancestor (LCCA) encoded both pathways. It seems
likely that the traditional MK pathway (e.g. menA-G) was
encoded by the LCCA, as men gene homologs are found
within both pathways. Upon diverging from the LCCA, Chla-
mydiaceae members could have independently acquired the first
four genes of the futalosine pathway (and lost the correspond-
ing men genes), potentially as a result of the differing degree of
reliance on host metabolites and ATP for energy production
between the two orders.
MTANs are required in a diverse array of biosynthetic path-
ways (37–39) that have yet to be implicated in Chlamydia (e.g.
polyamine biosynthesis, quorum sensing, DNA methylation,
etc.). Recently, however, Bonner et al. (63) have suggested that
the synthesis of menaquinone, and thus enzymatic function of
CT263, could be essential for Chlamydiaceae to maintain in a
“persistent” state inside the host cell. Persistence is a reversible
state of quiescence that Chlamydiaceae utilize as an immune
evasion strategy (64). These authors speculated that the trypto-
phan (Trp) content of key proteins could dictate translational
profiles during persistence as a means to respond to host cyto-
sol Trp depletion (e.g. IFN- and indoleamine dioxygenase acti-
TABLE 4
CT263-ligand hydrogen bonding information
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vation). Of particular note to this hypothesis, the chorismate
and MK pathways exhibit an extreme down-Trp selection in
Chlamydiaceae, indicating potential importance to survival in
the persistent state.
Our structural and kinetic observations indicate that
CT263 (and orthologs in other chlamydial species) likely
play an essential role in the menaquinone pathway. The crys-
tal structure of CT263 revealed an active site with increased
solvent exposure that resulted from the absence of the
prototypical MTAN dimer interface. Furthermore, CT263
required only minimal structural rearrangements for sub-
strate interaction. The structural information presented in
FIGURE 10. Multiple sequence alignment of CT263 and Chlamydiaceae orthologs. Limited structure-based alignment of CT263 and Chlamydiaceae
orthologs was generated using ClustalW (23) and rendered with ESPRIPT (24). The numbers above the sequences correspond to C. trachomatis CT263. Residues
are colored according to conservation (cyan, identical, and purple, similar) as judged by the BLOSUM62 matrix. Stars below the sequences correspond to
catalytic triad amino acid side chains (red) or the Chlamydiaceae-specific aromatic active site residue Trp-48 (black). Accession numbers are detailed under
“Experimental Procedures.”
FIGURE 11. CT263 structure naturally adopts closed-like conformation.
Structural comparison of CT263D161N-MTA (cyan) and S. enterica MTAN
open (red) and closed (purple) forms (PDB code: 4F1W), depicted in car-
toon ribbon format. Respective bound ligands are shown as balls-and-
sticks (MTA, cyan and ADE/TEG, purple). Dashed box highlights that CT263
active site is in a structurally similar conformation as the closed form of S.
enterica MTAN.
FIGURE 12. Molecular model of AFL binding to CT263 active site. 6-Amino-6-
deoxyfutalosine (yellow, balls-and-sticks) was manually aligned (within COOT (19,
20)) on the MTA molecule present within the CT263D161N-MTA cocrystal struc-
ture. CT263 is depicted in surface representation (20% transparency and colored
gray). Side chains within potential interaction distance of the isophthalic moiety
are colored purple and labeled. 2Fo  Fc electron density (countered at 1.0 )
corresponding to bound MTA is presented, highlighting structural conservation
between AFL and MTA.
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tandem with our emerging knowledge of MTAN-transition
state analogs in prototypical MTANs (53–56), provides a
promising starting point for the rational design of CT263-
based anti-chlamydial therapeutics.
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